Fortress Biotech’s Majority-Controlled Subsidiary, Journey Medical Corporation, Receives FDA Approval for Emrosi™ for Rosacea Treatment
Fortress Biotech, Inc. (NASDAQ: FBIO) announced through its majority-controlled subsidiary, Journey Medical Corporation, that the U.S. Food and Drug Administration (FDA) has approved Emrosiâ„¢ ...
GlobalData on MSN16h
FDA approves Journey Medical’s rosacea treatment Emrosi
The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand name for its 40mg minocycline ...
Journey gets FDA okay for Emrosi, releases preliminary Q3 earnings report
Journey Medical (DERM) received FDA approval for its drug Emrosi for the treatment of rosacea and released its preliminary Q3 ...
US FDA approves Journey Medical's drug for long-term skin condition
Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term ...
What's Going On With Journey Medical Stock Today?
Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug ...